Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 1,301–1,400 of 2,576
Walsh, C., Drinkenburg, W. H. I. M., & Ahnaou, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.020 · Cited by 39
“…Tyrosine Kinase Inhibitor llege Calcium channel blocker PPAR- receptor agonist iobeha a t W h p t t t t c ( a T f r 5 a 2 l s p l p o p c m s A f a e b b m w A d t ( 4 t s e F s e b m m t 2 u s t i w t t ( h m C. Walsh et al. / Neuroscience and B ggregate A 42/40 species (Scheuner et al., 1996).”
The secretases of Alzheimer's disease
Wolfe, M. S. (2003) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(03)54011-x · Cited by 35
Terai, K., Iwai, A., Kawabata, S., Sasamata, M., Miyata, K., & Yamaguchi, T. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02202-8 · Cited by 38
Van Uden, E., Carlson, G., St. George-Hyslop, P., Westaway, D., Orlando, R., Mallory, M., Rockenstein, E., & Masliah, E. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0772 · Cited by 32
Quantification of sub-femtomole amounts of Alzheimer amyloid β peptides
Potempska, A., Mack, K., Mehta, P., Kim, K. S., & Miller, D. L. (1999) · Amyloid · doi:10.3109/13506129908993283 · Cited by 35
Physical and genetic interaction of filamin with presenilin in Drosophila
Guo, Y., Zhang, S. X., Sokol, N. S., Cooley, L., & Boulianne, G. L. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.19.3499 · Cited by 42
Baker, L. D., Sambamurti, K., Craft, S., Cherrier, M., Raskind, M. A., Stanczyk, F. Z., Plymate, S. R., & Asthana, S. (2003) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.11.2.239 · Cited by 39
Incorporating biomarkers into clinical drug trials in Alzheimer's disease
Growdon, J. H. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3303 · Cited by 37
“In FAD, plasma levels of both A β 40 and A β 42 are increased[8]; these levels are increasedin some late-onset AD cases and A β 42 levels appear to be increased in some individuals at risk to develop AD [9].”
Metabotropic glutamate receptors in superficial laminae of the rat dorsal horn
Jia, H., Rustioni, A., & Valtschanoff, J. G. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19990809)410:4<627::aid-cne9>3.0.co;2-8 · Cited by 164
Hurtado, M. O., Kohler, I., & de Lange, E. C. M. (2018) · Bioanalysis · doi:10.4155/bio-2018-0135 · Cited by 34
Kaur, K., Kulkarni, Y. A., & Wairkar, S. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148905 · Cited by 38
Impact of an additional chronic BDNF reduction on learning performance in an Alzheimer mouse model
Psotta, L., Rockahr, C., Gruss, M., Kirches, E., Braun, K., Lessmann, V., Bock, J., & Endres, T. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00058 · Cited by 35
“…neuroprotective effects by reducing the cytotoxic effects of Aβ42 (Arancibia et al., 2008) and by stimulating the non-amyloidogenic pathway, resulting in a reduction of toxic Aβ species (Scheuner et al., 1996; Fu et al., 2002; Nishitomi et al., 2006; Thornton et al., 2006; Rohe et al., 2009).”
BackgroundLi, A., Zhou, C., Moore, J., Zhang, P., Tsai, T.-H., Lee, H., Romano, D., McKee, M. L., Schoenfeld, D., Serra, M. J., et al. (2011) · Current Alzheimer Research · doi:10.2174/156720511795563746 · Cited by 35
“AD brain contains A oligomers, which have been shown to impair neurotransmission [8].”
BackgroundSelf-citationPark, H., Na, D. L., Lee, J., Kim, J., & Ki, C. (2008) · Journal of Korean Medical Science · doi:10.3346/jkms.2008.23.2.213 · Cited by 37
Rationale for the development of an Alzheimer’s disease vaccine
Kwan, P., Konno, H., Chan, K. Y., & Baum, L. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1665453 · Cited by 33
Guest, F. L., Rahmoune, H., & Guest, P. C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-42667-5_8 · Cited by 34
Rudrabhatla, P., & Pant, H. C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1243 · Cited by 39
Genetic risk factors in familial Alzheimer's disease
Sorbi, S., Forleo, P., Tedde, A., Cellini, E., Ciantelli, M., Bagnoli, S., & Nacmias, B. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00308-6 · Cited by 39
Increased Alpha 7 Nicotinic Acetylcholine Receptor Protein Levels in Alzheimer’s Disease Patients
Chu, L., Ma, E. S. K., Lam, K., Chan, M. F., & Lee, D. H. S. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000082661 · Cited by 36
Mitochondrial mechanisms in amyloid beta peptide-induced cerebrovascular degeneration
Hsu, M., Sheu, J., Lin, C., Shen, M., & Hsu, C. Y. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.08.003 · Cited by 39
Caccamo, A., Magrì, A., & Oddo, S. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-51 · Cited by 38
“The strongest evidence for this position is derived from molecular genetic studies of the three genes (amyloid precursor protein, presenilin 1, and presenilin 2) that underlie familial AD cases, as they all modulate some aspect of Ab metabolism, increasing the propensity of Ab to aggregate [13-16].”
BackgroundLuteinizing hormone as a key player in the cognitive decline of Alzheimer's disease
Burnham, V. L., & Thornton, J. E. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.05.010 · Cited by 38
“Spontaneous mutation or inherited mutations of the APP gene, or presenilin 1 (PS1) or presenilin 2 (PS2) genes, which are subunits of γ-secretase, result in an increased accumulation of amyloid-β peptides (Morley and Farr, 2014; Scheuner et al., 1996; Zhang et al., 2000).”
BackgroundNowotny, P., Gorski, S. M., Han, S. W., Philips, K., Ray, W. J., Nowotny, V., Jones, C. J., Clark, R. F., Cagan, R. L., & Goate, A. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0805 · Cited by 37
Jacobsen, H., Reinhardt, D., Brockhaus, M., Bur, D., Kocyba, C., Kurt, H., Grim, M. G., Baumeister, R., & Loetscher, H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.35233 · Cited by 34
Pradier, L., Carpentier, N., Delalonde, L., Clavel, N., Bock, M., Buée, L., Mercken, L., Tocqué, B., & Czech, C. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0212 · Cited by 37
“…to an increase in production f the long form of the amyloid peptide, Ab1-42 (42 mino acids), compared to Ab1-40 (40 amino acids) in arrier patients (Scheuner et al., 1996), in transfected ells (Borchelt et al., 1996; Tomita et al., 1997; Xia et al., 997a), and in transgenic mice (Borchelt et al.,…”
BackgroundPKCε Deficits in Alzheimer's Disease Brains and Skin Fibroblasts
Khan, T. K., Sen, A., Hongpaisan, J., Lim, C. S., Nelson, T. J., & Alkon, D. L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141221 · Cited by 41
“A growing body of evidence shows that AD is associated with changes in peripheral tissues, outside the central nervous system [17–25].”
BackgroundHawkins, J., Harrison, D. C., Ahmed, S. F., Davis, R. P., Chapman, T. D., Marshall, I., Smith, B. B., Mead, T. L., Medhurst, A. D., Giblin, G. M. P., et al. (2011) · Neurodegenerative Diseases · doi:10.1159/000324511 · Cited by 36
Gadhave, K., Gehi, B. R., Kumar, P., Xue, B., Uversky, V. N., & Giri, R. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03414-9 · Cited by 36
Modeling autism spectrum disorders with human neurons
Beltrão-Braga, P. C. B., & Muotri, A. R. (2016) · Brain Research · doi:10.1016/j.brainres.2016.01.057 · Cited by 45
γ-Secretase: characterization and implication for Alzheimer disease therapy
Xu, M., Lai, M., Huang, Q., DiMuzio‐Mower, J., Castro, J. L., Harrison, T., Nadin, A. J., Neduvelil, J. G., Shearman, M. S., Shafer, J. A., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00126-4 · Cited by 37
“First, FAD mutations of PS1 and PS2 lead to an increased production of A 42 that may be resultant from altered -secretase activity in transfected cells or transgenic mice [1,6,24].”
BackgroundDvir, E., Elman, A., Simmons, D. A., Shapiro, I., Duvdevani, R., Dahan, A., Hoffman, A., & Friedman, J. E. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00014.x · Cited by 33
“These mice have a mutation of theamyloid precursor protein (APP) gene (APPK670N,M671L), known as the “Swedish mutation,” which causes increases in secreted Aß42 and Aß40 in brain (Citron et al. 1994; Scheuner et al. 1996).”
BackgroundExcitatory synaptic transmission is depressed in cultured hippocampal neurons of APP/PS1 mice
Priller, C., Mitteregger, G., Paluch, S., Vassallo, N., Staufenbiel, M., Kretzschmar, H. A., Jucker, M., & Herms, J. W. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.10.016 · Cited by 39
‘Alzheimer-like’ pathology in a murine model of arterial hypertension
Carnevale, D., & Lembo, G. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390939 · Cited by 34
Barritt, J. D., Younan, N. D., & Viles, J. H. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201704618 · Cited by 34
Enhanced accumulation of tau in doubly transgenic mice expressing mutant βAPP and presenilin-1
Samura, E., Shoji, M., Kawarabayashi, T., Sasaki, A., Matsubara, E., Murakami, T., Wuhua, X., Tamura, S., Ikeda, M., Ishiguro, K., et al. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.134 · Cited by 37
Presenilin endoproteolysis is an intramolecular cleavage
Brunkan, A. L., Martínez, M., Walker, E. S., & Goate, A. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.12.012 · Cited by 42
Cavani, S., Tamaoka, A., Moretti, A., Marinelli, L., Angelini, G., Stefano, S. D., Piombo, G., Cazzulo, V., Matsuno, S., Shoji, S., et al. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20001127)95:3<208::aid-ajmg5>3.0.co;2-j · Cited by 33
Intraneuronal amyloid β42 enhanced by heating but counteracted by formic acid
Ohyagi, Y., Tsuruta, Y., Motomura, K., Miyoshi, K., Kikuchi, H., Iwaki, T., Taniwaki, T., & Kira, J. (2006) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2006.06.010 · Cited by 40
Alzheimer's disease due to an intronic presenilin-1 (PSEN1 intron 4) mutation
Janssen, J. C., Hall, M., Fox, N. C., Harvey, R. J., Beck, J. A., Dickinson, A., Campbell, T., Collinge, J., Lantos, P. L., Cipolotti, L., et al. (2000) · Brain · doi:10.1093/brain/123.5.894 · Cited by 43
Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood
Lönneborg, A. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256296 · Cited by 36
Sato, N., Kamino, K., Tateishi, K., Satoh, T., Nishiwaki, Y., Yoshiiwa, A., Miki, T., & Ogihara, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6341 · Cited by 41
Okochi, M., Ishii, K., Usami, M., Sahara, N., Kametani, F., Tanaka, K., Fraser, P. E., Ikeda, M., Saunders, A. M., Hendriks, L., et al. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01378-1 · Cited by 36
Secretases as therapeutic targets for the treatment of Alzheimer's disease
Dominguez, D. I., Strooper, B. D., & Annaert, W. G. (2001) · Amyloid · doi:10.3109/13506120109007356 · Cited by 46
Jung, J. I., Premraj, S., Cruz, P. E., Ladd, T. B., Kwak, Y., Koo, E. H., Felsenstein, K. M., Golde, T. E., & Ran, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111553 · Cited by 35
Involvement of Luteinizing Hormone in Alzheimer Disease Development in Elderly Women
Rao, C. V. (2017) · Reproductive Sciences · doi:10.1177/1933719116658705 · Cited by 34
“The mutations in deterministic genes cause a rare form of the disease.(7,8) Healthy weight maintenance, prevention of type 2 diabetes, exercise, and drinking coffee and red wine in moderation appear to reduce the risks of AD.”
BackgroundShepherd, C. E., Affleck, A. J., Bahar, A. Y., Carew-Jones, F., & Halliday, G. M. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.10.025 · Cited by 32
Invertebrate Models of Alzheimer's Disease
Mhatre, S. D., Paddock, B. E., Saunders, A. J., & Marenda, D. R. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121204 · Cited by 41
“The A peptide is a proteolytic product of A PP [21, 22].”
Vascular Endothelial Barrier Dysfunction Mediated by Amyloid-β Proteins
Nagababu, E., Usatyuk, P. V., Enika, D., Natarajan, V., & Rifkind, J. M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1104 · Cited by 32
“Aβ1−42 has a greater tendency to form fibrils than Aβ1−40 [19].”
Cholesterol-depletion corrects APP and BACE1 misstrafficking in NPC1-deficient cells
Malnar, M., Košiček, M., Lisica, A., Marjanović, M. P., Krolo, A., Njavro, J. R., Omerbašić, D., Tahirović, S., & Hecimovic, S. K. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.04.002 · Cited by 39
Genetic and biochemical markers for Alzheimer's disease: recent developments
Mulder, C., Scheltens, P., Visser, J. J., van Kamp, G. J., & Schutgens, R. B. H. (2000) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/0004563001899898 · Cited by 35
Linking molecular motors to Alzheimer’s disease
Stokin, G. B., & Goldstein, L. S. B. (2006) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2005.12.085 · Cited by 37
Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family
Conidi, M. E., Bernardi, L., Puccio, G., Smirne, N., Muraca, M. G., Curcio, S. A. M., Colao, R., Piscopo, P., Gallo, M., Anfossi, M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001648 · Cited by 39
Molecular Targets in Alzheimer’s Disease: From Pathogenesis to Therapeutics
Cheng, X., Zhang, L., & Lian, Y. (2015) · BioMed Research International · doi:10.1155/2015/760758 · Cited by 38
Protein markers for Alzheimer disease in the frontal cortex and cerebellum
Verdile, G., Gnjec, A., Miklossy, J., Fonte, J., Veurink, G., Bates, K., Kakulas, B., Mehta, P. D., Milward, E. A., Tan, N., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000141848.45315.a6 · Cited by 32
Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer’s disease
Gandy, S. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00125-2 · Cited by 32
“within a membranous domain) but also because another class of FAD [58] acts by controlling the exact site(s) of gamma secretase cleavage [4,57].”
BackgroundTranscriptional Regulation of the Mouse Presenilin-1 Gene
Mitsuda, N., Roses, A. D., & Vitek, M. P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23489 · Cited by 38
Statin treatment and a disease-specific pattern of β-amyloid peptides in Alzheimer’s disease
Höglund, K., Syversen, S., Lewczuk, P., Wallin, A., Wiltfang, J., & Blennow, K. (2005) · Experimental Brain Research · doi:10.1007/s00221-005-2243-8 · Cited by 36
“…disease-causing mutations found in APP, Presenilin 1 (PS1) and Presenilin 2 (PS2) genes all lead to an upregulation of Ab40 and/or Ab42 peptides (Scheuner et al 1996); (2) individuals with trisomy 21 (with three APP genes) develop AD pathology in their fourth or fifth decade of life (Wisniewski…”
BackgroundNovel Role of Presenilins in Maturation and Transport of Integrin β1
Zou, K., Hosono, T., Nakamura, T., Shiraishi, H., Maeda, T., Komano, H., Yanagisawa, K., & Michikawa, M. (2008) · Biochemistry · doi:10.1021/bi7014508 · Cited by 32
Genes involved in Alzheimer's disease, a survey of possible candidates
Serretti, A., Artioli, P., Quartesan, R., & Ronchi, D. D. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-7410 · Cited by 38
Arendash, G. W., Su, G. C., Crawford, F., Bjugstad, K. B., & MULLAN, M. J. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00239-6 · Cited by 35
Biology of presenilins as causative molecules for Alzheimer disease
Nishimura, M., Yu, G., & George‐Hyslop, P. S. (1999) · Clinical Genetics · doi:10.1034/j.1399-0004.1999.550401.x · Cited by 32
Neurohormonal Signaling Pathways and the Regulation of Alzheimer β-Amyloid Precursor Metabolism
Gandy, S. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(99)00166-6 · Cited by 35
Tobeh, N. S., & Bruce, K. D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1259012 · Cited by 38
Olfactory Dysfunction and Alzheimer’s Disease: A Review
McLaren, A., & Kawaja, M. D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231377 · Cited by 37
“Under normal physiological conditions, PS1 and PS2 function to catalyze γ -secretase proteolytic cleavage of A (cid:2) PP. Similar to mutations in A β PP , mutations in PS1 and/or PS2 (cid:2) 42 andA (cid:2) 40 peptides[89,90].”
Cao, R., Elrod, L. T., Lehane, R. L., Kim, E., & Karlin, K. D. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b10689 · Cited by 35
Sultana, O. F., Hia, R. A., & Reddy, P. H. (2024) · Antioxidants · doi:10.3390/antiox13020202 · Cited by 32
TMP21 degradation is mediated by the ubiquitin‐proteasome pathway
Liu, S., Bromley‐Brits, K., Xia, K., Mittelholtz, J., Wang, R., & Song, W. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06497.x · Cited by 34
“Presenilin (PS) mutant forms have been shown to increase c-secretase activity, resulting in elevated Ab42 production (Borchelt et al., 1996, 1997; Scheuner et al., 1996).”
BackgroundSurprising toxicity and assembly behaviour of amyloid β-protein oxidized to sulfone
Maiti, P., Piacentini, R., Ripoli, C., Grassi, C., & Bitan, G. (2010) · Biochemical Journal · doi:10.1042/bj20101391 · Cited by 36
Somatostatin and Cognitive Function in Neurodegenerative Disorders
Tuboly, G., & Vécsei, L. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955713804484794 · Cited by 33
What Can Rodent Models Tell Us About Cognitive Decline in Alzheimer's Disease?
Davis, S., & Laroche, S. (2003) · Molecular Neurobiology · doi:10.1385/mn:27:3:249 · Cited by 38
Trambauer, J., Sarmiento, R. M. R., Fukumori, A., Feederle, R., Baumann, K., & Steiner, H. (2019) · EMBO Reports · doi:10.15252/embr.201947996 · Cited by 32
Secretases as therapeutic targets for Alzheimer’s disease
Woo, H., Baik, S., Park, J. S., Gwon, A., Yang, S.-H., Yun, Y., & Jo, D. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.132 · Cited by 35
Akbari, Y., Hitt, B. D., Murphy, M. P., Dagher, N. N., Tseng, B. P., Green, K. N., Golde, T. E., & LaFerla, F. M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.136 · Cited by 33
Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness
Shoji, M., & Kanai, M. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3306 · Cited by 31
Huang, X., Yee, B. K., Nag, S., Chan, S. T. H., & Tang, F. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00242-5 · Cited by 36
Hoffmann, J., Pietrzik, C. U., Kummer, M. P., Twiesselmann, C., Bauer, C., & Herzog, V. (1999) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549904700311 · Cited by 34
“Several growth factors such as FGF are known to bind to heparin (Schlessinger et al. 1995).”
BackgroundGu, M., & Viles, J. H. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.04.009 · Cited by 34
AβPeptide Originated from Platelets Promises New Strategy in Anti-Alzheimer’s Drug Development
Inyushin, M. Y., Sanabria, P., Rojas, L. V., Kucheryavykh, Y. V., & Kucheryavykh, L. Y. (2017) · BioMed Research International · doi:10.1155/2017/3948360 · Cited by 32
“Platelets are also the primary source of Aβ peptide in human blood (∼90%) [21], and this secreted peptide is similar to that found in the senile plaques of AD patients and is similarly increased in vivo by the presenilin 1 and presenilin 2 and APPmutations linked to familial AD [22].”
BackgroundAD biomarker discovery in CSF and in alternative matrices
Sancesario, G. M., & Bernardini, S. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.08.008 · Cited by 32
Takeda, S., Sato, N., Rakugi, H., & Morishita, R. (2010) · Molecular BioSystems · doi:10.1039/c003148h · Cited by 33
Ha, C., & Park, C. B. (2006) · Langmuir · doi:10.1021/la0601511 · Cited by 36
Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials
Donohue, M., Moghadam, S. H., Roe, A. D., Sun, C., Edland, S. D., Thomas, R. G., Petersen, R. C., Sano, M., Galasko, D. R., Aisen, P. S. S., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.07.156 · Cited by 32
siRNA against presenilin 1 (PS1) down regulates amyloid β42 production in IMR-32 cells
Kandimalla, R. J. L., Wani, W. Y., Binukumar, B. K., & Gill, K. D. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-2 · Cited by 31
“On the other hand studies on mutant presenilins in transgenic animals have shown increase in the relative level of Ab42 production [23,24].”
BackgroundYasuda, M., Maeda, S., Kawamata, T., Tamaoka, A., Yamamoto, Y., Kuroda, S., Maeda, K., & Tanaka, C. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.2.220 · Cited by 32
Mirnics, Z. K., Mirnics, K., Terrano, D. T., Lewis, D. A., Sisodia, S. S., & Schor, N. F. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001389 · Cited by 32
Presenilins, amyloid-β and Alzheimer's disease
Lamb, B. T. (1997) · Nature Medicine · doi:10.1038/nm0197-28 · Cited by 33
Presenilin 1 Binds to Amyloid Precursor Protein Directly
Waragai, M., Imafuku, I., Takeuchi, S., Kanazawa, I., Oyama, F., Udagawa, Y., Kawabata, M., & Okazawa, H. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7488 · Cited by 30
Presenilin-1 Protects against Neuronal Apoptosis Caused by Its Interacting Protein PAG
Zhou, Y., Zhang, W., Easton, R., Ray, J. W., Lampe, P. A., Jiang, Z., Brunkan, A. L., Goate, A., Johnson, E. M., & Wu, J. Y. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0472 · Cited by 33
“…such as APP, Notch, and Ire1p (Borch- 0969-9961/02 $35.00 © 2002 Elsevier Science (USA) All rights reserved. elt et al., 1996, 1997; Duff et al., 1996; Scheuner et al., 1996; De Strooper et al., 1998, 1999; Annaert et al., 1999; Katayama et al., 1999; Ni et al., 2001; Niwa et al., 1999; Wolfe et…”
InfluentialSun, X., Cole, G. M., Chu, T., Xia, W., Galasko, D., Yamaguchi, H., Tanemura, K., Frautschy, S. A., & Takashima, A. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00265-2 · Cited by 31
Cellular and molecular basis of beta-amyloid precursor protein metabolism
Xu, H. (1998) · Frontiers in Bioscience · doi:10.2741/a283 · Cited by 2
Lambert, M., Velasco, P., Viola, K., & Klein, W. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601876 · Cited by 29
Alzheimer′s disease: A review of recent developments
Salawu, F., Umar, J., & Olokoba, A. (2011) · Annals of African Medicine · doi:10.4103/1596-3519.82057 · Cited by 39
Brain Aging and Late-Onset Alzheimer’s Disease: A Matter of Increased Amyloid or Reduced Energy?
Mecocci, P., Baroni, M., Senin, U., & Boccardi, V. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179903 · Cited by 32
Pigment Epithelium-Derived Factor Plays a Role in Alzheimer's Disease by Negatively Regulating Aβ42
Huang, M., Qi, W., Fang, S., Jiang, P., Yang, C., Mo, Y., Dong, C., Li, Y., Zhong, J., Cai, W., et al. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0628-1 · Cited by 30
“Aβ originates from APP, which must undergo two sequential endoproteolytic steps of proteolysis by two crucial enzymes known as γ-secretase and β-secretase [2, 39].”
BackgroundMouse models of Alzheimer's disease for preclinical research
Watamura, N., Sato, K., & Saido, T. C. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105361 · Cited by 31
Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice
Wang, H.-C., Zhang, T., Kuerban, B., Jin, Y.-L., Le, W., Hara, H., Fan, D.-S., Wang, Y., Tabira, T., & Chui, D.-H. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1546-4 · Cited by 30
Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer’s disease
Woodhouse, A., Shepherd, C. E., Sokolova, A., Carroll, V. L., King, A. E., Halliday, G. M., Dickson, T. C., & Vickers, J. C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0458-z · Cited by 30
Loreto, S. D., Falone, S., D'Alessandro, A., Santini, S. J., Sebastiani, P., Cacchio, M., & Amicarelli, F. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.05.006 · Cited by 33
“ELISA-based detection of Aβ We used a mAb-based ELISA kit for the quantitative determination of Aβ in cortex homogenates (Scheuner et al., 1996).”
Takeda, S., Sato, N., Uchio‐Yamada, K., Yu, H., Moriguchi, A., Rakugi, H., & Morishita, R. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000338704 · Cited by 30
Presenilins and the γ-secretase: still a complex problem
Small, D. H., Klaver, D. W., & Foa, L. C. (2010) · Molecular Brain · doi:10.1186/1756-6606-3-7 · Cited by 37
“PS mutations are linked to g-secretase activity [21].”
Background
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.